Company profile

Rondo Therapeutics

Privately held: no public share price (Private clinical-stage biotech; $67M Series A in 2022 and a 2024 Lilly collaboration, no listing found. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.prnewswire.com/news-releases/rondo-therapeutics-closes-67-million-series-a-financing-to-advance-next-generation-immuno-oncology-platform-for-solid-tumors-301493486.html]) · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
RNDO-564
Phase 1
CD28 x Nectin-4Multispecific antibody
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.